You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RET NSCLC

Showing 1 - 25 of 3,592
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

    Terminated
    Has Results
    • ALK-positive Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Irvine, California
    • +3 more
    Aug 30, 2021

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

    Terminated
    • Non-small Cell Lung Cancer
    • +2 more
    • Brussels, Belgium
    • +18 more
    Aug 23, 2022

    Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

    Active, not recruiting
    • Advanced Nonhaematologic Malignancies
    • Philadelphia, Pennsylvania
    • +20 more
    Sep 23, 2022

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

    Active, not recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +39 more
    • pralsetinib (BLU-667)
    • Phoenix, Arizona
    • +65 more
    Nov 10, 2022

    Pralsetinib to Best Available Therapy in RET-Fusion Positive

    Enrolling by invitation
    • RET-fusion Non Small Cell Lung Cancer
    • +16 more
      • New York, New York
      • +2 more
      Aug 9, 2021

      Non Small Cell Lung Cancer Trial in Seoul (Vandetanib)

      Completed
      • Non Small Cell Lung Cancer
      • Seoul, Korea, Republic of
      • +1 more
      Dec 4, 2020

      Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation Trial in New York (RXDX-105)

      Completed
      • Non Small Cell Lung Cancer
      • +3 more
      • New York, New York
        Memorial Sloan Kettering Cancer Center 1275 York Avenue
      Sep 30, 2020

      RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

      Not yet recruiting
      • RET-altered Non Small Cell Lung Cancer
      • +3 more
      • Chang chun, Jilin, China
        Jinlin Province Cancer Hosipital
      Dec 21, 2022

      Advanced Solid Tumor Trial in Los Angeles (EP0031)

      Recruiting
      • Advanced Solid Tumor
      • Los Angeles, California
      • +3 more
      Dec 1, 2022

      NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Shanghai, Shanghai, China
      • +1 more
      Mar 17, 2022

      NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +3 more
      • Scottsdale, Arizona
      • +84 more
      Oct 10, 2022

      NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Berazategui, Buenos Aires, Argentina
      • +195 more
      Jan 30, 2023

      Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

      Active, not recruiting
      Has Results
      • Solid Tumor
      • Medullary Thyroid Cancer
      • Guangzhou, Guangdong, China
      • +12 more
      May 9, 2022

      Non Small Cell Lung Cancer Trial in United States (Ponatinib)

      Completed
      Has Results
      • Non Small Cell Lung Cancer
      • Orange, California
      • +4 more
      Dec 8, 2019

      Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

      Recruiting
      • Non Small Cell Lung Cancer
      • +4 more
      • Irvine, California
      • +15 more
      Mar 9, 2022

      Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

      Recruiting
      • Lung Non-Small Cell Carcinoma
      • +4 more
      • Tampa, Florida
        Moffitt Cancer Center
      Aug 16, 2022

      Resistance-associated Mutations in Metastatic Lung Cancer

      Recruiting
      • Lung Cancer
      • Liquid biopsy
      • Monza, MB, Italy
        Fondazione IRCCS San Gerardo dei Tintori
      Oct 10, 2023

      Advanced Solid Tumor Trial in Chengdu (KL590586 Capsule)

      Enrolling by invitation
      • Advanced Solid Tumor
      • KL590586 Capsule
      • Chengdu, Sichuan, China
        Sichuan Kelun Botai Biopharmaceutical Co.
      Feb 23, 2022

      NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)

      Recruiting
      • Non-small Cell Lung Cancer
      • London, United Kingdom
        Univeristy College London Hospital
      Feb 22, 2022

      China With Non-Small-Cell Lung Cancer That is Unable to be

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
        • (no location specified)
        May 16, 2023